TAMEY FLEISCHHAUER: Open Payments
NPI 1962152611 · LUBBOCK, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,793 in 84 payments from 19 companies in 2025. Trend: 2023 $241 · 2024 $3,159 · 2025 $2,793
Food & beverage: $2,793
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 35 | $714 |
| UCB, Inc. | 18 | $460 |
| Amgen Inc. | 5 | $394 |
| Neurocrine BioSciences, Inc. | 8 | $288 |
| ARGENX US, INC. | 1 | $123 |
| Otsuka America Pharmaceutical, Inc. | 1 | $123 |
| Phathom Pharmaceuticals, Inc. | 1 | $123 |
| Eisai Inc. | 2 | $122 |
| TG Therapeutics, Inc. | 1 | $114 |
| Janssen Biotech, Inc. | 1 | $100 |
Products named: QULIPTA, INGREZZA, UPLIZNA, UBRELVY, Briviact, Zilbrysq, VOQUEZNA, REXULTI.
Industry payments across TX — which companies pay providers there.
